Interferon-alpha as maintenance therapy in patients with multiple myeloma [4]

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1981-

  Yalcin, B ^a   Dogan, M ^a   Buyukcelik, A ^a   Doruk, H ^a   Tek, I ^a   Demirkazik, A ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MELPHALAN; PREDNISONE;

CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LETTER; MAINTENANCE THERAPY; MULTIPLE MYELOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; MULTIPLE MYELOMA; SURVIVAL RATE;

EID: 28444486914     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi390     Document Type: Letter

References (2)

1. Schaar CG, Kluin-Nelemans HC, Marvelle C et al. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005; 16: 634-639.
2. The Myeloma Trialist's Collaborative Group Secretariat based at Imperial Cancer Research Fund/Medical Research Council Clinical Trial Service Unit. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034.